Evaluating human papillomavirus vaccination programs

Emerging Infectious Diseases

Volumn 10, Issue 11, 2004, Pages 1915-1923

  Taira, Al V ^a,b,d   Neukermans, Christopher P ^b   Sanders, Gillian D ^b,c,e  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c DUKE UNIVERSITY   (United States)

^d PNM   (United States)

^e DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE TRANSMISSION; EVALUATION; FEMALE; HIGH RISK PATIENT; HUMAN; INFECTION PREVENTION; INFECTION RATE; MAJOR CLINICAL STUDY; MALE; QUALITY ADJUSTED LIFE YEAR; SEXUAL BEHAVIOR; UTERINE CERVIX CANCER; VACCINATION; VIRUS INFECTION; VIRUS SHEDDING; WART VIRUS;

EID: 7644236858     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid1011.040222     Document Type: Article

References (39)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer. 1999;80:827-41.
2. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer. 1999;83:18-29.
3. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: a world-wide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995;87:796-802.
4. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-9.
5. Breitburd F, Coursaget P. Human papillomavirus vaccines. Semin Cancer Biol. 1999;9:431-44.
6. McNeil C. HPV vaccines for cervical cancer move toward clinic, encounter social issues [news]. J Natl Cancer Inst. 1997;89:1664-6.
7. Koutsky LA. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002;347:1645-51.
8. Paavonen J, Halttunen M, Hansson BG, Nieminen P, Rostila T, Lehtinen M. Prerequisites for human papillomavirus vaccine trial: results of feasibility studies. J Clin Virol. 2000;19:25-30.
9. Schiller J, Lowy D. Papillomavirus-like particle vaccines. J Natl Cancer Inst Monogr. 2001;28:50-4.
10. Garnett GP, Waddell HC. Public health paradoxes and the epidemiological impact of an HPV vaccine. J Clin Virol. 2000;19:101-11.
11. Zimet GD, Mays RM, Winston Y, Kee R, Dickes J, Su L. Acceptability of human papillomavirus immunization. J Womens Health Gend Based Med. 2000;9:47-50.
12. Lauman EO. The social organization of sexuality in America: sexual practices in the United States. Chicago: University of Chicago Press; 1994.
13. National Center for Health Statistics. Sexual activity and contraceptive practices among teenagers in the United States, 1988 and 1995. Vital and Health Statistics. Series 23. Hyattsville (MD): The Center; 2001.
14. Michael RT, Wadsworth J, Feinleib J, Johnson AM, Laumann EO, Wellings K. Private sexual behavior, public opinion, and public health policy related to sexually transmitted diseases: a US-British comparison. Am J Public Health. 1998;88:749-54.
15. Jacobs MV, Walboomers JM, Snijders PJ, Voorhorst FJ, Verheijen RH, Fransen-Daalmeijer N, et al. Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int J Cancer. 2000;87:221-7.
16. Hildesheim A, Gravitt P, Schiffman MH, Kurman RJ, Barnes W, Jones S, et al. Determinants of genital human papillomavirus infection in low-income women in Washington, D.C. Sex Transm Dis. 1993;20:279-85.
17. Melkert PW, Hopman E, van den Brule AJ, Risse EK, van Diest PJ, Bleker OP, et al. Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is age-dependent. Int J Cancer. 1993;53:919-23.
18. Bauer HM, Hildesheim A, Schiffman MH, Glass AG, Rush BB, Scott DR, et al. Determinants of genital human papillomavirus infection in low-risk women in Portland, Oregon. Sex Transm Dis. 1993;20:274-8.
19. Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol. 2000;151:1158-71.
20. Moscicki AB, Shiboski S, Broering J, Powell K, Clayton L, Jay N, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr. 1998;132:277-84.
21. Hildesheim A, Schiffman MH, Gravitt PE, Glass AG, Greer CE, Zhang T, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis. 1994;169:235-40.
22. Rothenberg RB. The geography of gonorrhea. Empirical demonstration of core group transmission. Am J Epidemiol. 1983;117:688-94.
23. Boily MC, Masse B. Mathematical models of disease transmission: a precious tool for the study of sexually transmitted diseases. Can J Public Health. 1997;88:255-65.
24. Stoner BP, Whittington WL, Hughes JP, Aral SO, Holmes KK. Comparative epidemiology of heterosexual gonococcal and chlamydial networks: implications for transmission patterns. Sex Transm Dis. 2000;27:215-23.
25. Sanders G, Taira A. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis. 2003;9:37-48.
26. Goldie SJ, Kuhn L, Denny L, Pollack A, Wright TC. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA. 2001;285:3107-15.
27. Koutsky LA, Holmes KK, Critchlow CW, Stevens CE, Paavonen J, Beckmann AM, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med. 1992;327:1272-8.
28. National Cancer Institute. SEER Cancer Statistics Review 1973-1998. Atlanta: The Institute; 2001.
29. Bernstein AB, Thompson GB, Harlan LC. Differences in rates of cancer screening by usual source of medical care. Data from the 1987 National Health Interview Survey. Med Care. 1991;29:196-209.
30. Hughes JP, Garnett GP, Koutsky L. The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology. 2002;13:631-9.
31. Brown AD, Garber AM. Cost-effectiveness of 3 methods to enhance the sensitivity of Papanicolaou testing. JAMA. 1999;281:347-53.
32. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA. 2003;290:781-9.
33. Mangtani P, Hall AJ, Normand CE. Hepatitis B vaccination: the cost effectiveness of alternative strategies in England and Wales. J Epidemiol Community Health. 1995;49:238-44.
34. Taira A, Neukermans C, Sanders G. Modeling subpopulation dynamics in vaccine cost effectiveness studies [abstract]. Med Decis Making. 2003;23:562.
35. Brisson M. Economic evaluation of vaccination programs: the impact of herd immunity. Med Decis Making. 2003;23:76-82.
36. Edmunds WJ, Medley GF, Nokes DJ. Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective. Stat Med. 1999;18:3263-82.
37. Clements D. Partial uptake of varicella vaccine and the epidemiological effect on varicella disease in 11 day-care centers in North Carolina. Arch Pediatr Adolesc Med. 2001;155:455-61.
38. Dagan R. National hepatitis A vaccine immunization program aimed exclusively at toddlers in an endemic country resulted in >90% reduction in morbidity in all age groups. Chicago: Infectious Diseases Society of America; 2002.
39. Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004;96:604-15.